Cargando…
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
Foundational therapy for heart failure and a reduced ejection fraction consists of a combination of an angiotensin receptor–neprilysin inhibitor, a beta‐blocker, a mineralocorticoid receptor antagonist and a sodium–glucose co‐transporter 2 (SGLT2) inhibitor. However, the conventional approach to the...
Autores principales: | Packer, Milton, McMurray, John J.V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360176/ https://www.ncbi.nlm.nih.gov/pubmed/33704874 http://dx.doi.org/10.1002/ejhf.2149 |
Ejemplares similares
-
Insights into foundational therapies for heart failure with reduced ejection fraction
por: McMurray, John J. V., et al.
Publicado: (2022) -
Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022) -
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019) -
Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis
por: Burnett, Heather, et al.
Publicado: (2017) -
What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?
por: Packer, Milton
Publicado: (2020)